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Summary
Background Group B Streptococcus (GBS) disease is a leading cause of neonatal death, but its long-term effects have 
not been studied after early childhood. The aim of this study was to assess long-term mortality, neurodevelopmental 
impairments (NDIs), and economic outcomes after infant invasive GBS (iGBS) disease up to adolescence in Denmark 
and the Netherlands.
Methods For this cohort study, children with iGBS disease were identified in Denmark and the Netherlands using 
national medical and administrative databases and culture results that confirmed their diagnoses. Exposed children 
were defined as having a history of iGBS disease (sepsis, meningitis, or pneumonia) by the age of 89 days. For each 
exposed child, ten unexposed children were randomly selected and matched by sex, year and month of birth, and 
gestational age. Mortality data were analysed with the use of Cox proportional hazards models. NDI data up to 
adolescence were captured from discharge diagnoses in the National Patient Registry (Denmark) and special 
educational support records (the Netherlands). Health care use and household income were also compared between 
the exposed and unexposed cohorts.
Findings 2258 children—1561 in Denmark (born from Jan 1, 1997 to Dec 31, 2017) and 697 in the Netherlands (born 
from Jan 1, 2000 to Dec 31, 2017)—were identified to have iGBS disease and followed up for a median of 14 years 
(IQR 7–18) in Denmark and 9 years (6–11) in the Netherlands. 366 children had meningitis, 1763 had sepsis, and 
129 had pneumonia (in Denmark only). These children were matched with 22 462 children with no history of iGBS 
disease. iGBS meningitis was associated with an increased mortality at age 5 years (adjusted hazard ratio 4·08 [95% CI 
1·78–9·35] for Denmark and 6·73 [3·76–12·06] for the Netherlands). Any iGBS disease was associated with an 
increased risk of NDI at 10 years of age, both in Denmark (risk ratio 1·77 [95% CI 1·44–2·18]) and the Netherlands 
(2·28 [1·64–3·17]). A history of iGBS disease was associated with more frequent outpatient clinic visits (incidence 
rate ratio 1·93 [95% CI 1·79–2·09], p<0·0001) and hospital admissions (1·33 [1·27–1·38], p<0·0001) in children 
5 years or younger. No differences in household income were observed between the exposed and unexposed cohorts.
Interpretation iGBS disease, especially meningitis, was associated with increased mortality and a higher risk of NDIs 
in later childhood. This previously unquantified burden underlines the case for a maternal GBS vaccine, and the need 
to track and provide care for affected survivors of iGBS disease.
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Introduction 
Group B Streptococcus (GBS), specifically Streptococcus 
agalactiae, is a leading cause of invasive bacterial disease 
in neonates and young infants (0–89 days).1,2 Estimates 
suggest that the burden affects all regions worldwide, 
with more than 21·7 million pregnant women affected, 
55 000 (uncertainty range [UR] 12 000–104 000) stillbirths, 
319 000 (145 000–653 000) infant cases of invasive GBS 
(iGBS) disease, and 90 000 (36 000–169 000) deaths in 
infants younger than 3 months annually.3
Assessing the total burden associated with iGBS disease 
is crucial to design strategies for service provision and 
prevention, including evaluation of the potential benefit of 
maternal GBS vaccines that are currently in develop­
ment.4–6 However, there are important data gaps, notably 
regarding the long­term health and economic outcomes of 
individuals after recovering from iGBS disease. Patients 
who survive iGBS disease might be at risk of increased 
mortality later in life and of long­term neuro developmental 
impairments (NDIs), including intellectual, motor, vision, 
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and hearing impairments. A meta­analysis of NDI 
after iGBS disease included 18 small studies (a total of 
453 partici pants) only after meningitis.7 This result high­
lights a key data gap regarding the long­term adverse 
outcomes after sepsis, which represents the majority of 
patients with iGBS infection.7 Data for patients older than 
2 years were few and collected primarily in the 1970s. Most 
studies did not include a comparator cohort and, import­
antly, did not consider gestational age, a major driver 
of NDI, in analyses.7–14 Hence, robust, up­to­date data on 
impair ments that manifest in childhood or adolescence, 
and especially after GBS sepsis, are inadequate. Economic 
outcome data are even more scarce, with only one small 
study of patients up to the age of 2 years from the UK.15
In this study, we constructed cohorts of children who 
had had iGBS infection in early infancy using national 
databases in Denmark and the Netherlands. Our object­
ives were to: (1) describe children with iGBS infection; 
(2) examine excess mortality during and after iGBS disease 
in comparison with the unexposed cohorts; (3) estimate 
the risk of NDI up until adolescence, com paring exposed 
cohorts with unexposed cohorts; and (4) assess the 
effects of iGBS disease on long­term health­care use and 
household income.
Methods 
Study design and participants 
We did a nationwide matched cohort study using Danish 
population­based medical and administrative registries 
(born Jan 1, 1997–Dec 31, 2017) and Dutch population 
registries (born Jan 1, 2000–Dec 31, 2017), up to 21 years 
of age in Denmark and up to 18 years of age in the 
Netherlands. Exposed children were defined as having a 
history of iGBS disease (sepsis, meningitis, or pneu monia) 
by the age of 89 days. Unexposed children without iGBS 
disease were randomly selected and matched at a ratio 
of 10:1 on sex, birth month and year, and gestational age 
(<28 weeks, 28–36 weeks, and ≥37 weeks) to each exposed 
child.
In Denmark, the Medical Birth Registry and the Danish 
National Patient Registry were used to identify children 
with iGBS disease. The Danish National Patient Registry 
contains records of all admissions to Danish non­
psychiatric hospitals since 1977, and outpatient clinic 
and emergency room visits since 1995. GBS menin gitis, 
sepsis, and pneumonia were defined on the basis 
of discharge diagnoses with the use of International 
Classification of Diseases (ICD)­10 codes (appendix 3 
p 10).16–18 To assess the compre hensiveness of discharge 
ICD­10 codes in identi fying iGBS disease in Denmark, 
we compared the GBS cohort from 1997–2003 with the 
North Denmark Bacteraemia Research Database, which 
has registered all patients from the north Denmark 
region diagnosed with culture­proven bacteraemia.19 
The unexposed cohort was sampled from the Danish 
Medical Birth Registry and the Danish Civil Registration 
System.17 The index date corresponded with the birth 
date.
See Online for appendix 3
Research in context
Evidence before this study
Invasive group B Streptococcus (iGBS) infection is a leading 
cause of neonatal mortality and morbidity worldwide, 
but important knowledge gaps exist regarding the long-term 
outcomes of patients who survive iGBS disease. A 2017 
systematic review and meta-analysis of outcomes after iGBS 
found only 18 small studies (n=453 patients) assessing 
neurodevelopmental impairment (NDI), almost exclusively 
before the age of 2 years and without comparator groups. 
All studies focused on NDIs after meningitis, and not after 
sepsis, which is more common. Only one study described the 
economic costs linked to iGBS disease following children up to 
the age of 2 years. In November, 2020, Pubmed was searched 
with terms similar to the 2017 review relating to “Streptococcus 
agalactiae [MesH]”, “group B streptococcus”, and “disability” 
“impairment” with no restrictions for date and language. 
We did not identify any new published studies meeting the 
inclusion criteria.
Added value of this study
To our knowledge, our study is the first to quantify the major 
enduring effect of iGBS disease on health outcomes of survivors 
up until adolescence, including mortality, NDI, health-care use, 
and household income. We used linked national health-care 
databases from Denmark and the Netherlands to generate 
cohorts with more than 24 000 children included. In Denmark, 
the risk of a diagnosis of moderate or severe NDI by the age of 
10 years was two times higher among children with history 
of iGBS disease compared with unexposed children. Similarly, 
children in the Netherlands with a history of iGBS disease were 
twice as likely to require educational support, including 
enrolment in special needs schools, compared with unexposed 
children. Both a history of GBS sepsis and GBS meningitis were 
associated with NDIs and a need for educational support. 
Throughout childhood, frequencies of outpatient clinic visits 
and hospital admissions were higher in children who had a 
history of iGBS disease than in those without iGBS disease 
during early infancy. Although GBS meningitis was associated 
with higher mortality in children younger than 5 years in both 
Denmark and the Netherlands, increased mortality during or 
after GBS sepsis was observed only in the Netherlands.
Implications of all the available evidence
Our findings show that the burden of iGBS disease is 
unacceptably high, despite intrapartum prophylactic antibiotic 
strategies and advanced neonatal care in high-income 
countries. The burden of iGBS disease is higher in lower-income 
and middle-income countries, where most at-risk births and 
the majority of cases occur. Improved preventive interventions, 
such as maternal GBS vaccines, are urgently needed.
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In the Netherlands, patients with iGBS disease were 
identified from the Netherlands Reference Laboratory 
for Bacterial Meningitis, which receives approximately 
90% of isolates cultured from the blood or cerebrospinal 
fluid (CSF) of infants with invasive infection from 
microbiology laboratories.20,21 All infants with CSF or 
blood culture positive for GBS, or both, were eligible for 
inclusion. Meningitis was defined as positive CSF culture 
or both positive CSF and blood cultures. Sepsis was 
defined as a positive blood culture only. The unexposed 
cohort was randomly selected with the use of the PeriNed 
perinatal registry (a database covering approximately 
99% of all births in the Netherlands) and the Municipal 
Personal Records Database (which records mortality 
data).22 More information on the databases in both 
countries is provided in appendix 3 (pp 5–9). The study 
was approved by the Danish Data Protection Agency 
(record number 2015­57­0002). In the Netherlands, the 
study protocol (EPI­408) was submitted to the Centre 
for Clinical Expertise at the National Institute for Public 
Health and the Environment. The study protocol was 
exempted from further approval by an ethical research 
committee, according to Dutch law for medical research 
involving human subjects.
Procedure 
The first objective was to examine the clinical char­
acteristics of children with iGBS disease. For each child, 
information on sex, year and month of birth, multiplicity, 
gestational age, and birthweight was obtained from 
population registries (appendix 3 pp 10, 11). In Denmark, 
the age of iGBS onset was calculated from the first 
admis sion to hospital date for iGBS disease. In the 
Netherlands, the first reported date of illness, mostly 
the first date a culture was taken (in 97·4% of patients), 
was used to calculate the age at onset. iGBS disease was 
categorised as either early onset (0–6 days old) or late 
onset (7–89 days old).
The second objective was to establish mortality during 
and after iGBS disease. All­cause mortality during the 
first 3 months and 5 years of life were assessed, on the 
basis of data from the Danish Civil Registration System17 
and the Dutch Municipal Personal Records Database. In 
Denmark, mortality during hospital admission for iGBS 
disease was also examined (data were not available in 
the Netherlands).
The third objective was to look at the risk of NDIs. NDIs 
were defined differently in the two cohorts. In Denmark, 
we obtained information on NDIs from the Danish 
National Patient Registry18 using ICD­10 codes for mental, 
behavioural, and nervous system disorders. We assessed 
the motor, hearing, vision, cognitive, and social or be­
havioural domains, and categorised impairments by 
severity (mild, moderate, or severe; definitions specified 
in appendix 3 pp 11–13). Overall, an NDI was defined as 
an impairment in any domain, and a multidomain NDI 
as an impairment in more than one domain.9
In the Netherlands, special educational support was 
used as a surrogate marker for an NDI. National databases 
covering primary school registration and special education 
were used to identify children who received education in 
special needs schools (considered as a moderate or severe 
NDI) or who received additional support in regular schools 
(considered as a mild NDI).
The fourth objective was to examine long­term health­
care use and household income. In Denmark, data on 
the number of days of hospital care, hospital admissions, 
and outpatient clinic visits were obtained from the 
Danish National Patient Registry and calculated for each 
year of follow­up (data were not available in the 
Netherlands). The outpatient clinic visits included 
contact with hospital­based (ambulatory) specialty clinics 
but not with private practice specialists or general 
practitioners.
In Denmark, data on individual income from the 
Income Statistics Register23 were used to derive annual 
household income by summing the gross income of 
each cohort member’s parents. This number was then 
converted to Euros.24 In the Netherlands, household 
income was ascer tained from a registry database of 
standard ised disposable household income after adjust­
ment for family size and taxes. Data on the percentage 
of gross household income from welfare payments 
were also obtained from the same registry database. 
In both countries, incomes were adjusted to the 2018 
currency values with the use of the country­specific 
World Bank gross domestic product deflator.25 Of note, 
household income was assessed for each year after the 
first year in which the invasive iGBS episode occurs, 
not at birth, and was not adjusted for baseline income. 
Rather, the household income of the exposed group was 
compared with the household income of the families 
with unexposed children who were matched to the 
exposed group.
Statistical analysis 
All children were followed up from birth until death, 
emigration, or until the end of the study (Dec 31, 2017), 
whichever came first. We computed the mortality risk 
during the acute iGBS episode, first 3 months, and first 
5 years of life (objective 2). Survival curves were plotted 
with the use of the Kaplan­Meier technique (appendix 3 
pp 20, 21). Mortality rates were computed per 1000 person­
years of follow­up. Hazard ratios (HRs), adjusted for the 
matching factors, were computed with the use of Cox 
proportional hazards regression and compared children 
with iGBS disease with unexposed children. The pro­
portional hazards assumption was assessed graphically 
with the use of log–log plots and was found to be 
appropriate.
For NDI analyses (objective 3), cohorts were restricted to 
children who survived the first 3 months of life. Risks of 
overall, domain­specific, and multidomain NDI, as well as 
special educational needs, were assessed at different ages 
For the Municipal Personal 
Records Database see 
http://www.cbs.nl
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(Denmark, 5, 7, 10, 15, and 20 years; the Netherlands, 5, 7, 
10, and 11 years). We included only children followed up 
until at least the corresponding cutoff age. To quantify 
the association between iGBS disease and NDI, we 
used a modified Poisson regression with robust variance 
estimators to estimate risk ratios (RRs) adjusted for the 
matching variables.26
Health­care use in Denmark was assessed annually 
(objective 4), and compared between cohorts with the 
use of negative binomial regression models. The average 
Figure 1: Study flowcharts showing children with iGBS disease and gestational age-matched unexposed cohorts in Denmark (A) and the Netherlands (B)
Of 1525 iGBS cases, 1398 were included in the NDI and economic analyses (after including only those who survived iGBS and excluding pneumonia). This cohort was 
further restricted in the NDI analyses to those who were alive at age of 5 years (n=1293), 7 years (n=1179), and 10 years (n=969). iGBS=invasive group B Streptococcus. 
NDI=neurodevelopmental impairments.
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138 meningitis
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household income was also described. Sensitivity 
analyses compared exposed cohorts with a second un­
exposed cohort matched on sex and birth month and 
year, but not on gestational age categories, to evaluate the 
relative effect of iGBS and potential contribution of 
prematurity. In Denmark, data on gestational age were 
missing for 28 neo nates, therefore they were excluded 
from the primary analyses. In Denmark, statistical 
analyses were done using SAS version 9.4, and in the 
Netherlands, they were done using SPSS Statistics 
version 25.0 and STATA version 16.
Role of the funding source 
The funder of the study had no role in in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
Source populations encompassed 1 297 383 livebirths 
(Jan 1, 1997–Dec 31, 2017) in Denmark and 3 144 350 live­
births (Jan 1, 2000–Dec 31, 2017) in the Netherlands. 
Overall, we identified 2258 children with a history of 
iGBS disease, to whom 22 462 children with no history 
of iGBS disease were matched (figure 1). Children with 
iGBS disease were followed up for a median of 14 years 
(IQR 7–18) in Denmark and 9 years (6–11) in the 
Netherlands. In Denmark, 1295 (83%) of 1561 ex posed 
children had iGBS with onset in the first 72 h after birth, 
compared with 392 (56%) of 697 in the Netherlands. 
Most exposed children had a history of GBS sepsis 
(table 1), occurring most often in the first 72 h of life 
(1122/1264 [88·8%] in Denmark and 335/499 [67·1%] in 
the Netherlands). A lower percentage of children had 
GBS meningitis (table 1), often after the first week of life 
(88/168 [52·4%] in Denmark and 113/198 [57·1%] in the 
Netherlands). The early onset versus the late onset ratio 
of cases differed between countries and was stable over 
time (table 2).
Mortality risk in the exposed cohort in the first 89 days 
of life was 2·3% (95% CI 1·7–3·2%) in Denmark 
and 7·6% (5·6–9·5%) in the Netherlands. In the un­
exposed cohort, mortality was considerably lower: 1·7% 
(1·5–1·9%) in Denmark and 1·7% (1·4–2·1%) in the 
Netherlands. To estimate the potential contribution of 
pre maturity to these mortality risks, we calculated 
mortal ity in the unexposed cohorts that were not 
matched for gestational age (0·3% [95% CI 0·2–0·4%] 
in Denmark and 0·4% [0·3–0·6%] in the Netherlands), 
which was lower than those matched for gestational 
age. Preterm infants (gestational age <37 weeks) with a 
history of iGBS disease had a higher mortality rate 
during the first 3 months of life than did infants carried 
to term (gestational age ≥37 weeks). In Denmark, 6·7% 
(95% CI 4·5–10·0%) of preterm and 1·1% (0·7–1·9%) of 
term children with iGBS disease died during the study 
period. In the Netherlands, 15·5% (10·0–20·4%) of 
preterm children and 5·0% (3·3–7·1%) of term children 
died. In Denmark, 33 of 1561 children with iGBS (2·1%) 
died during their hospital stay for iGBS.
In the Netherlands, the 5­year mortality rate was higher 
in the exposed cohort than the unexposed cohort (table 3). 
5­year HRs in Denmark were 4·08 (95% CI, 1·78–9·35) for 
iGBS meningitis, 0·79 (0·54–1·16) for iGBS sepsis, and 
0·59 (0·14–2·55) for iGBS pneu monia. In the Netherlands, 
the corres ponding HRs were 6·73 (3·76–12·06) for iGBS 
meningitis and 3·23 (2·19–4·76) for iGBS sepsis (table 3).
Of the 1525 children who survived iGBS disease in 
Denmark, 1293 were included in analyses of long­term 
impairment by the age of 5 years and 969 by the age of 
10 years. In the Netherlands, 489 of the 646 patients who 
survived iGBS reached the age of mandatory education 
(5 years); 16 (3·2%) of them were not found in the national 
database and were considered lost to follow­up (figure 1B). 
iGBS was associated with an overall risk of NDI by age 










Meningitis 168 (10·8%) NA 198 (28·4%) NA
Sepsis 1264 (81·0%) NA 499 (71·6%) NA
Pneumonia 129 (8·3%) NA ·· NA
Sex
Female 700 (44·8%) 6942 (44·8%) 309 (44·3%) 3081 (44·3%)
Male 861 (55·2%) 8559 (55·2%) 388 (55·7%) 3880 (55·7%)
Gestational age
<28 weeks 53 (3·4%) 421 (2·7%) 30 (4·3%) 291 (4·2%)
28–36 weeks 274 (17·6%) 2740 (17·7%) 151 (21·7%) 1510 (21·7%)
≥37 weeks 1234 (79·1%) 12 340 (79·6%) 516 (74·0%) 5160 (74·1%)
Multiplicity
Singleton 1460 (93·5%) 14 242 (91·9%) 649 (93·1%) 6385 (91·7%)
Twins 93 (6·0%) 1213 (7·8%) 44 (6·3%) 554 (8·0%)
Higher order 8 (0·5%) 46 (0·3%) <5 (<0·7%) 21 (0·3%)
Birthweight (kg) 3·5 (2·9–3·9) 3·4 (2·9–3·8) 3·3 (2·7–3·7) 3·3 (2·7–3·7)
Maternal age (years) 30·4 (27·0–33·7) 30·4 (27·2–33·8) 30·4 (26·7–33·8) 31·1 (27·8–34·4)
Numbers are presented as n (%) or median (IQR). In the Netherlands, the number of recruited children with a history of 
iGBS disease only partly reflects the country-level incidence of iGBS disease, because cases were restricted to those that 
could be linked between several datasets. iGBS=invasive group B Streptococcus. NA=not applicable.
Table 1: Characteristics of children with iGBS disease and members of a matched comparison cohort in 










1997–99 312 (89·4%) 37 (10·6%) ·· ··
2000–05 437 (86·4%) 69 (13·6%) 109 (66·9%) 54 (33·1%)
2006–11 310 (80·9%) 73 (19·1%) 138 (65·7%) 72 (34·3%)
2012–17 268 (83·0%) 55 (17·0%) 198 (61·1%) 126 (38·9%)
Numbers are presented as n (%). Early-onset disease was defined as age 0–6 days 
and late-onset disease as age 7–89 days. GBS=invasive group B Streptococcus.
Table 2: Prevalence of early-onset and late-onset GBS disease across 
different time frames in the study period
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10 years (RR 1·77 [95% CI 1·44–2·18] in Denmark and 
2·28 [1·64–3·17] in the Netherlands; appendix 3 pp 15, 16). 
In Denmark, 45 (4·6%) of 969 of patients who survived 
iGBS disease had moderate or severe NDI at 10 years, 
compared with 234 (2·5%) of 9519 in the unexposed 
cohort (RR 1·82 [95% CI 1·33–2·49]). This proportion 
was even lower in the unexposed cohort not matched by 
gestational age than the matched un exposed cohort (2·1%). 
A similar pattern was observed in the Netherlands: among 
patients who survived iGBS, 27 (7·1%) of 380 received 
some form of special edu cational support by the age of 
7 years and 36 (14·3%) of 252 by 10 years, compared with 
111 (2·9%; aged 7 years) of 3776 and 157 (6·2%; aged 
10 years) of 2527 in the unexposed cohort, and 92 (1·9%; 
aged 7 years) of 4844 and 185 (5·3%; aged 10 years) of 3495 
in the unexposed cohort not matched by gestational age. 
Children with a history of GBS meningitis had a higher 
fre quency of impairment than did those previously 
diagnosed with GBS sepsis only (figure 2). Both children 
with a history of GBS meningitis and GBS sepsis had a 
higher NDI risk than did the unexposed group (figure 2; 
appen dix 3 pp 15, 16). Similarly, both early­onset and late­
onset iGBS were associated with an increased NDI risk 
(appendix 3 pp 15, 16).
Consistently higher frequencies of moderate and severe 
motor and cognitive impairments were observed in 
children who survived iGBS disease than in unexposed 
children (appendix 3 pp 15, 16). In Denmark, the co­
occurrence of moderate or severe impairment in two or 
more domains by the age of 10 years was observed in 
19 (2·0%) of 969 patients who survived iGBS disease, 
and in 90 (0·9%) of 9519 unexposed children (RR 1·98 
[95% CI 1·22–3·21]; appendix 3 p 15).
In Denmark, patients who survived iGBS disease 
had higher rates of outpatient clinic visits, hospital 
admissions, and a higher number of days in hos pital 
per year than did unexposed children (figure 3). In 
negative binomial regression models accounting for 
differences in follow­up time, a history of iGBS disease 
was asso ciated with more frequent outpatient clinic 
visits (incidence rate ratio 1·93 [95% CI 1·79–2·09], 
p<0·0001) and hospital admissions (1·33 [1·27–1·38], 
p<0·0001) in children 5 years or younger. Similar 
results were obtained in analyses of children aged 
10 years or younger for outpatient clinic visits (1·83 
[1·67–2·00], p<0·0001) and hospital admis sions (1·43 
[1·37–1·50], p<0·0001). No differences in household 
in come were observed (appendix 3 p 22). Dutch data 
also showed no clear difference in the receipt of welfare 
payments (appendix 3 p 23).
Discussion 
We observed that children with a history of iGBS disease, 
particularly those with meningitis, had a higher mortality 
rate than did children without a history of iGBS disease. 
In Denmark, NDIs, including moder ate and severe 
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survived iGBS disease. In the Netherlands, these children 
required more educational support. The rates of use of 
health care were also higher in children who had iGBS 
disease. However, the average household income did not 
differ between the families of exposed and unexposed 
children. Overall, our results show that iGBS disease 
continues to affect children and their families well beyond 
the neonatal period.
Both in Denmark and the Netherlands, mortality was 
higher during early infancy for children with iGBS 
disease than it was for unexposed children. However, 
mortality in the first months of life in Denmark was 
Figure 2: Proportion of children with NDIs among those with invasive GBS disease compared with unexposed children matched on gestational age in Denmark (A) and the Netherlands (B)
(A) Proportions of children with NDIs of different severities at different ages in the Danish study population are shown for the exposed and unexposed cohorts. For these four panels, the NDI outcomes 
include: cognitive domain, motor domain, overall NDI, and multi-domain NDIs. Of the 1525 children who survived GBS disease in Denmark, 1293 (by age 5 years) and 969 (by age 10 years) were 
included in analyses of long-term impairment. (B) The proportion of children with NDIs in the study population from the Netherlands. Children enrolled in special needs schools are presented as 
having moderate or severe NDI. 489 of the 646 patients who survived GBS in the Netherlands reached the age of mandatory education; 16 (3·2%) were not found in the national database and were 
considered lost to follow-up. The diagnosis of NDIs was defined cumulatively—namely, that each child was considered to have impairments based on all follow-up information available up to the 
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considerably lower than in the Netherlands and lower 
than the mortality reported for other high­income 
countries; for example, in one study in the UK, the case 
fatality rate was 6·2%,27 and in a systematic review, it was 
4·7% (95% CI 3·3–6·1%) during an iGBS infection.28 
This lower mortality rate could represent a real difference 
in mortal ity or more likely could be related to the 
differences in the study populations. In terms of missed 
cases, it is possible that in Denmark, ICD­based case 
identification selectively missed some GBS infections on 
the day of birth and these cases might have a higher 
mortality rate. In addition, the Danish cohort included 
patients with GBS disease who only had pneu monia, 
which might be associated with lower mortality.29 These 
patients were not included in the Netherlands’ system, 
which diagnoses patients on the basis of positive cultures. 
Because of the small number of children with a diagnosis 
of GBS pneumonia in Denmark, we might have been 
under powered to compare the mortality risk during or 
after GBS pneumonia. It is important to note that the 
Danish cohort potentially included some children with 
GBS infections not con firmed by culture. We validated 
the discharge diagnosis codes for a subgroup of children 
diagnosed by culture in the north region of Denmark 
(1997–2013). In the Netherlands, only culture­proven 
infections were included. This selectiveness might have 
contributed to the observed difference, because a higher 
mortality rate has been reported in culture­proven (~7%) 
versus clinically probable (~1%) sepsis cases,30 although 
the definition of ICD­coded and clinically probable cases 
could differ.
Maternal GBS colonisation is a known risk factor for 
both prematurity and iGBS infection31 and there might be 
an increased risk of iGBS disease in preterm infants.32 
Adjustment for gestational age reduced the association 
between mortality and iGBS, and the adjusted HRs for 
children with a history of GBS meningitis were lower 
(4·08 in Denmark and 6·73 in the Netherlands) compared 
with those in unadjusted analyses (22·88 and 14·77; 
appendix 3 p 14).
Because few deaths were observed after the first 
3 months of life, we were unable to analyse mortality 
among children who survived the acute episode. Further­
more, because of the low numbers, we were unable to 
assess differences in the mortality rates of children with 
a history of iGBS pneumonia. The uncertainty in this 
clinical diagnosis because of the frequent co­occurrence 
of sepsis emphasises the importance of doing prospective 
studies on patients with iGBS pneumonia with clear 
laboratory and clinical criteria.
Data on NDI after iGBS disease are sparse. We found 
that patients who survived iGBS sepsis or meningitis are at 
a considerably higher risk of NDI than are unexposed 
children, regardless of the outcome or method used to 
identify disability. Our longitudinal data also showed a 
progressive increase in NDI frequency as children grow 
up, which illustrates the importance of long­term follow­up 
to capture the burden of iGBS disease. In a systematic 
review of 18 studies on NDIs after iGBS disease, a 18% risk 
of moderate or severe NDI was reported in patients who 
survived GBS meningitis (n=453) followed up for a median 
of 18 months or longer. The few studies identified that had 
follow­up data in children older than 2 years were primarily 
done in the 1970s,33,34 and were limited by small sample 
sizes. Data on NDI in patients who survived GBS sepsis 
were few. Our study addressed these major data gaps by 
assessing NDI up until adolescence, and by including data 
from more than 1500 children who survived iGBS sepsis. 
The results for iGBS sepsis have major implications for 
estimating the global burden of iGBS. An excess risk of 
disability after GBS sepsis, although lower than that after 
menin gitis, might be a higher attributable risk given that 
GBS sepsis is much more common. Additionally, since 
this is a lifetime risk of disability, years lived with disability 
and disability­adjusted life­years could be considerable. 
Hence our findings will be important when considering 
the potential effect and cost­effectiveness of interventions, 
such as intrapartum antibiotic prophylaxis and maternal 
vaccination.
Families’ economic circumstances might plausibly be 
affected by the severe illness of a child and subsequent 
Figure 3: Health-care use among children with invasive GBS disease compared with unexposed children that 
were matched by gestational age in Denmark
(A) Outpatients clinic visits. (B) Number of hospital admissions (bars) and mean number of days in hospital 
(red line corresponds to exposed children; blue line corresponds to unexposed children). 95% CIs of age-specific 
means are presented for each bar. Hospital admissions for acute GBS were excluded in the analysis of number of 
days of hospitalisation in the first year of life. GBS=group B Streptococcus disease.
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NDIs might result in costs both to health­care systems 
and to families. The only previous study assessing the 
economic costs of iGBS disease (n=138) reported two­
times higher health and social care costs over the first 
2 years of life.15 Our results, based on an at least five­times 
longer follow­up than the previous study, are consistent. In 
Denmark, patients who survived iGBS had a higher rate of 
health­care use. Furthermore, we found that a higher 
frequency of health­care visits persisted until at least the 
age of 10 years. However, we did not find a measurable 
effect on household income in either country. Nevertheless, 
similar average incomes in ex posed and unexposed groups 
do not preclude an effect on families’ expenditure to 
support their child. It is probable that the national health 
systems in both countries covered or compensated most of 
the direct health­care­related costs. But, given the much 
higher health­care use and the need for special educational 
support, iGBS disease could substan tially affect family 
expenditure and income in countries with less access to 
health care and social support.
Our study has several strengths, notably a large sample 
size, a large number of unexposed comparison children, 
a multinational design, long­term follow­up up until 
adolescence, and high­quality data. However, the study 
also has limitations. In appendix 3 p 18, we list the 
differences in the capture of iGBS disease and outcome 
data between the two countries, and potential biases. 
Although differences in case selection (diagnosis­based 
vs culture­based) might explain some of the disparities in 
mortality outcomes, the comparison with a cohort that is 
unmatched by gestational age suggests that exposure 
mis classification is not the only explanation. NDI data 
in Denmark were restricted to patients diagnosed in a 
hospital setting, leading to a probable underestimation of 
vision and hearing problems. Another limitation was our 
use of special education support as a proxy for NDI in the 
Netherlands. Our estimates of special education needs 
after GBS meningitis are consistent with the results of 
the meta­analysis on NDIs after GBS disease by Kohli­
Lynch and colleagues7 and we estimated relative risk 
using a matched unexposed cohort; however, we cannot 
rule out that children with NDIs might have been missed 
in both exposed and unexposed groups. Indeed, if the 
severity of the NDI was too high to permit school attend­
ance, these children could have been missed, leading to 
the underestimation of NDIs.
iGBS disease, particularly meningitis, during early 
infancy has a persistent effect on the lives of affected 
children and their families. In low­income and middle­
income countries, the long­term effect might be even 
greater, and future studies should address outcomes 
in such countries. Furthermore, in Denmark and the 
Netherlands, risk­based policies on intrapartum anti­
biotic prophylaxis were adopted nearly two decades ago. 
Despite this, the high risk of fatal outcomes and NDIs 
suggest that additional preventive measures, such as a 
maternal GBS vaccine to protect infants, are needed to 
minimise associated morbidity and mortality long after 
an infection with iGBS.
Contributors
MJ and JEL conceived the idea for this study. MJ, JEL, MWB, EH­P, 
HTS, and BdG designed the study. EH­P, MNvK, and BPG prepared the 
data for analysis. KKS and EH­P created the list of ICD codes used to 
identify iGBS cases in Denmark. JC, PP, and EH­P created the list of 
ICD codes used to identify neurodevelopmental impairment in 
Denmark. EH­P, MNvK, BdG, BPG, and SRP analysed and interpreted 
the data and prepared figures and tables. EH­P, MNvK, and BPG 
prepared the first draft of the manuscript. EH­P, MNK, BPG, MJ, HTS, 
MWB, and JEL had final responsibility for the decision to submit for 
publication. EH­P and MNK verified the underlying data. AvdE, SJS, 
and SJMH provided suggestions on the design of the study and 
contributed to interpretation of results. AvdE generated microbiological 
data that were used for analyses in the Netherlands. All authors provided 
input to the overall direction and content of the paper, reviewed each 
draft of the paper, and reviewed and approved the final version.
Declaration of interests
AvdE received grants from Pfizer for research on pneumococcal 
infections (investigator initiated project IIR WI173197) and for research 
on meningococcal infections (investigator initiated project IIR WI242174), 
outside the submitted work; participated in the Advisory Boards of Pfizer, 
GlaxoSmithKline, and Sanofi­Pasteur; and did consultancy activities for 
GlaxoSmithKline and Merck Sharp & Dohme (fees paid to Amsterdam 
University Medical Center). HTS reports that the Department of Clinical 
Epidemiology is involved in studies with institutional funding from 
regulators and from various pharmaceutical companies, as research 
grants to and administered by Aarhus University. None of these studies 
are related to the current study. All other authors declare no competing 
interests.
Data sharing
Although local data governing bodies in Denmark and in the 
Netherlands do not authorise individual level data from these electronic 
cohorts to be shared, datasets with selected aggregated data are available 
from the corresponding author on reasonable request.
Acknowledgments
We thank PeriNed and Statistics Netherlands for their cooperation and 
for making their valuable data available for this study. In Denmark, 
we would like to thank the teams that manage the Danish Civil 
Registration System and the North Denmark Bacteraemia Research 
Database. We are also grateful to members of the project’s Scientific 
Advisory Group, in particular Ajoke Sobanjo­ter Meulen for valuable 
input. The findings and conclusions in this report are those of the 
authors and do not necessarily represent the official position of 
the US Centers for Disease Control and Prevention. This work was 
supported by a grant (OPP1180644) from the Bill & Melinda Gates 
Foundation to the London School of Hygiene & Tropical Medicine 
(Principal Investigator, Joy Lawn) and the Stichting Remmert Adriaan 
Laan Fonds.
References
1 Lawn JE, Bianchi­Jassir F, Russell NJ, et al. Group B streptococcal 
disease worldwide for pregnant women, stillbirths, and children: 
why, what, and how to undertake estimates? Clin Infect Dis 2017; 
65 (suppl 2): S89–99.
2 Le Doare K, Heath PT. An overview of global GBS epidemiology. 
Vaccine 2013; 31 (suppl 4): D7–12.
3 Seale AC, Bianchi­Jassir F, Russell NJ, et al. Estimates of the 
burden of group B streptococcal disease worldwide for pregnant 
women, stillbirths, and children. Clin Infect Dis 2017; 
65 (suppl 2): S200–19.
4 Heath PT. Status of vaccine research and development of vaccines 
for GBS. Vaccine 2016; 34: 2876–79.
5 Kobayashi M, Schrag SJ, Alderson MR, et al. WHO consultation on 
group B streptococcus vaccine development: report from a meeting 
held on 27­28 April 2016. Vaccine 2019; 37: 7307–14.
6 Lin SM, Zhi Y, Ahn KB, Lim S, Seo HS. Status of group B 
streptococcal vaccine development. Clin Exp Vaccine Res 2018; 
7: 76–81.
Articles
www.thelancet.com/child-adolescent   Vol 5   June 2021 407
7 Kohli­Lynch M, Russell NJ, Seale AC, et al. Neurodevelopmental 
impairment in children after group B streptococcal disease 
worldwide: systematic review and meta­analyses. Clin Infect Dis 
2017; 65 (suppl 2): S190–99.
8 Ben Hamouda H, Ben Haj Khalifa A, Hamza MA, et al. 
Clinical outcome and prognosis of neonatal bacterial meningitis. 
Arch Pediatr 2013; 20: 938–44.
9 Blencowe H, Lee AC, Cousens S, et al. Preterm birth­associated 
neurodevelopmental impairment estimates at regional and global 
levels for 2010. Pediatr Res 2013; 74 (suppl 1): 17–34.
10 Horn KA, Zimmerman RA, Knostman JD, Meyer WT. Neurological 
sequelae of group B streptococcal neonatal infection. Pediatrics 1974; 
53: 501–04.
11 Libster R, Edwards KM, Levent F, et al. Long­term outcomes of 
group B streptococcal meningitis. Pediatrics 2012; 130: e8–15.
12 Schröder H, Tessmar J, Paust H, Keller P, Hanefeld F. Long­term 
sequelae of neonatal group B streptococcal septicemia/meningitis 
(author’s transl). Monatsschr Kinderheilkd 1982; 130: 153–56.
13 Wee LY, Tanugroho RR, Thoon KC, et al. A 15­year retrospective 
analysis of prognostic factors in childhood bacterial meningitis. 
Acta Paediatr 2016; 105: e22–29.
14 Zhu M, Zhu J, Li H, Liu P, Lin Z. Clinical analysis and follow­up of 
neonatal purulent meningitis caused by group B Streptococcus. 
Zhonghua Er Ke Za Zhi 2014; 52: 133–36.
15 Schroeder EA, Petrou S, Balfour G, Edamma O, Heath PT. 
The economic costs of group B streptococcus (GBS) disease: 
prospective cohort study of infants with GBS disease in England. 
Eur J Health Econ 2009; 10: 275–85.
16 Bliddal M, Broe A, Pottegård A, Olsen J, Langhoff­Roos J. 
The Danish Medical Birth Register. Eur J Epidemiol 2018; 33: 27–36.
17 Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration 
System as a tool in epidemiology. Eur J Epidemiol 2014; 29: 541–49.
18 Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, 
Sørensen HT. The Danish National Patient Registry: a review of 
content, data quality, and research potential. Clin Epidemiol 2015; 
7: 449–90.
19 Schønheyder HC, Søgaard M. Existing data sources for clinical 
epidemiology: The North Denmark Bacteremia Research Database. 
Clin Epidemiol 2010; 2: 171–78.
20 Netherlands Reference Laboratory for Bacterial Meningitis 
(AMC/RIVM). Bacterial meningitis in the Netherlands: 
Annual Report 2016. Amsterdam: University of Amsterdam, 2017. 
https://www.amc.nl/web/specialismen/medische­microbiologie/
medische­microbiologie/mmi­nederlands­referentielaboratorium­
voor­bacteriele­meningitis­nrlbm.htm (accessed July 14, 2020).
21 Bijlsma MW, Bekker V, Brouwer MC, Spanjaard L, van de Beek D, 
van der Ende A. Epidemiology of invasive meningococcal disease in 
the Netherlands, 1960–2012: an analysis of national surveillance 
data. Lancet Infect Dis 2014; 14: 805–12.
22 PeriNed. Perinatale Zorg in Nederland (2000­2017) annual reports 
(2000–2017). 2019. https://www.perined.nl/jaarboek­zorg/jaarboek­
zorg­2002­2014 (accessed July 14, 2020).
23 Baadsgaard M, Quitzau J. Danish registers on personal income and 
transfer payments. Scand J Public Health 2011; 39 (suppl): 103–05.
24 European Central Bank Statistical Data Warehouse. 2020. 
https://sdw.ecb.europa.eu/quickview.do?SERIES_KEY=120.
EXR.A.DKK.EUR.SP00.A (accessed July 14, 2020).
25 World Bank. GDP deflator: World Bank national accounts data, 
and OECD National Accounts data files. 2020. https://data.worldbank.
org/indicator/NY.GDP.DEFL.ZS (accessed Dec 20, 2019).
26 Chen W, Qian L, Shi J, Franklin M. Comparing performance 
between log­binomial and robust Poisson regression models for 
estimating risk ratios under model misspecification. 
BMC Med Res Methodol 2018; 18: 63.
27 O’Sullivan CP, Lamagni T, Patel D, et al. Group B streptococcal 
disease in UK and Irish infants younger than 90 days, 2014–15: 
a prospective surveillance study. Lancet Infect Dis 2019; 19: 83–90.
28 Madrid L, Seale AC, Kohli­Lynch M, et al. Infant group B 
streptococcal disease incidence and serotypes worldwide: 
systematic review and meta­analyses. Clin Infect Dis 2017; 
65 (suppl 2): S160–72.
29 Seale AC, Blencowe H, Zaidi A, et al. Neonatal severe bacterial 
infection impairment estimates in South Asia, sub­Saharan Africa, 
and Latin America for 2010. Pediatr Res 2013; 74 (suppl 1): 73–85.
30 Trijbels­Smeulders M, de Jonge GA, Pasker­de Jong PC, et al. 
Epidemiology of neonatal group B streptococcal disease in 
the Netherlands before and after introduction of guidelines for 
prevention. Arch Dis Child Fetal Neonatal Ed 2007; 92: F271–76.
31 Bianchi­Jassir F, Seale AC, Kohli­Lynch M, et al. Preterm birth 
associated with group B streptococcus maternal colonization 
worldwide: systematic review and meta­analyses. Clin Infect Dis 
2017; 65 (suppl 2): S133–42.
32 Oddie S, Embleton ND. Risk factors for early onset neonatal group B 
streptococcal sepsis: case­control study. BMJ 2002; 325: 308.
33 Chin KC, Fitzhardinge PM. Sequelae of early­onset group B 
hemolytic streptococcal neonatal meningitis. J Pediatr 1985; 
106: 819–22.
34 Wald ER, Bergman I, Taylor HG, Chiponis D, Porter C, Kubek K. 
Long­term outcome of group B streptococcal meningitis. Pediatrics 
1986; 77: 217–21.
